Skip to main
OCS

OCS Stock Forecast & Price Target

OCS Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Oculis Holding AG's recent developments in its biopharmaceutical pipeline have resulted in significant positive metrics, including the FDA granting Breakthrough Therapy Designation for its candidate OCS-05, which underscores the urgency in addressing acute neuro-ophthalmic conditions such as acute optic neuritis (AON) and non-arteritic anterior ischemic optic neuropathy (NAION). The Company's OCS-01 has demonstrated robust efficacy results, achieving all primary endpoints in the DIAMOND-1 trial and showcasing its capability to effectively target the retinal layer, enhancing prospects for market introduction. Furthermore, the projected peak sales for Oculis's therapeutic candidates indicate a promising market opportunity, with estimates suggesting $1.2 billion for AON and $623 million for NAION by 2035, bolstered by a diversified pipeline aimed at addressing unmet needs in ophthalmic and retinal diseases.

Bears say

Oculis Holding AG reported a net loss of CHF 16.9 million in the third quarter of 2025, reflecting ongoing financial challenges as the company invests in the late-stage development of its product portfolio. The anticipated high operating expenses associated with the PIONEER-1 trial of OCS-05, alongside significant risks of clinical trial failure and competition within the biopharmaceutical sector, contribute to a negative outlook. Additionally, the historical ineffectiveness of neuroprotection agents and the barriers presented by invasive treatment options for conditions like diabetic macular edema further complicate the company's market position and future profitability.

OCS has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Oculis Holding AG and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Oculis Holding AG (OCS) Forecast

Analysts have given OCS a Strong Buy based on their latest research and market trends.

According to 7 analysts, OCS has a Strong Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Oculis Holding AG (OCS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.